Why Zomedica Stock Isn’t Worth Buying Right Now 2021-05-07T20:45:13-04:00May 7th, 2021| share this article! If Truforma truly is a game-changer, there’s hope the company could grab part of a potential $10.5 billion animal diagnostics market. Read More share this article! Related Posts Transformative Projects And Acquisitions Shape Masdar’s Renewable Energy Strategy, Says COO May 21st, 2024 Will Medtronic Stock See Higher Levels Post Q4 Results After 5% Gains This Year? May 21st, 2024 Gaining 12% Year To Date, Will Q1 Results Drive Target’s Stock Higher? May 21st, 2024 LVMH, Walmart And Home Depot Earnings Highlight Shift In Consumer Spending May 21st, 2024